Synergy Pharmaceuticals (SGYP) Stake Decreased by Rhumbline Advisers

Rhumbline Advisers trimmed its stake in shares of Synergy Pharmaceuticals (NASDAQ:SGYP) by 16.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 217,593 shares of the biopharmaceutical company’s stock after selling 41,815 shares during the quarter. Rhumbline Advisers owned about 0.09% of Synergy Pharmaceuticals worth $485,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its position in shares of Synergy Pharmaceuticals by 71.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,405,377 shares of the biopharmaceutical company’s stock valued at $8,820,000 after acquiring an additional 1,417,177 shares during the period. Alyeska Investment Group L.P. lifted its position in shares of Synergy Pharmaceuticals by 42.0% during the 3rd quarter. Alyeska Investment Group L.P. now owns 2,355,681 shares of the biopharmaceutical company’s stock valued at $6,831,000 after acquiring an additional 696,911 shares during the period. Hikari Power Ltd lifted its position in shares of Synergy Pharmaceuticals by 26.7% during the 4th quarter. Hikari Power Ltd now owns 1,900,000 shares of the biopharmaceutical company’s stock valued at $4,237,000 after acquiring an additional 400,000 shares during the period. Schwab Charles Investment Management Inc. lifted its position in shares of Synergy Pharmaceuticals by 11.2% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 1,051,408 shares of the biopharmaceutical company’s stock valued at $2,345,000 after acquiring an additional 106,222 shares during the period. Finally, Swiss National Bank lifted its position in shares of Synergy Pharmaceuticals by 13.5% during the 4th quarter. Swiss National Bank now owns 421,650 shares of the biopharmaceutical company’s stock valued at $940,000 after acquiring an additional 50,000 shares during the period. Hedge funds and other institutional investors own 53.08% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of SGYP stock opened at $1.87 on Friday. The company has a quick ratio of 3.88, a current ratio of 4.33 and a debt-to-equity ratio of -21.05. Synergy Pharmaceuticals has a twelve month low of $1.68 and a twelve month high of $4.84. The firm has a market cap of $448.92, a P/E ratio of -1.83 and a beta of 1.17.

Synergy Pharmaceuticals (NASDAQ:SGYP) last announced its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.03. The business had revenue of $9.40 million during the quarter, compared to the consensus estimate of $7.12 million. Synergy Pharmaceuticals had a negative return on equity of 652.66% and a negative net margin of 1,333.76%. The firm’s quarterly revenue was up 840.0% on a year-over-year basis. research analysts expect that Synergy Pharmaceuticals will post -0.52 earnings per share for the current fiscal year.

Several brokerages recently weighed in on SGYP. Oppenheimer restated a “hold” rating on shares of Synergy Pharmaceuticals in a research report on Thursday, March 22nd. HC Wainwright set a $7.00 price objective on Synergy Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, March 5th. Zacks Investment Research downgraded Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, March 1st. Finally, BidaskClub downgraded Synergy Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, February 23rd. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. Synergy Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $8.08.

TRADEMARK VIOLATION WARNING: “Synergy Pharmaceuticals (SGYP) Stake Decreased by Rhumbline Advisers” was posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.tickerreport.com/banking-finance/3334478/synergy-pharmaceuticals-sgyp-stake-decreased-by-rhumbline-advisers.html.

About Synergy Pharmaceuticals

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Want to see what other hedge funds are holding SGYP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Synergy Pharmaceuticals (NASDAQ:SGYP).

Institutional Ownership by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Analysts Anticipate Culp, Inc.  to Post $0.43 Earnings Per Share
Analysts Anticipate Culp, Inc. to Post $0.43 Earnings Per Share
Brokerages Anticipate 1-800-Flowers  to Post -$0.12 Earnings Per Share
Brokerages Anticipate 1-800-Flowers to Post -$0.12 Earnings Per Share
Patrick Industries  vs. Ply Gem  Critical Review
Patrick Industries vs. Ply Gem Critical Review
Barrett Business Services  & Its Competitors Financial Survey
Barrett Business Services & Its Competitors Financial Survey
Contrasting Fresh Del Monte Produce  & Limoneira
Contrasting Fresh Del Monte Produce & Limoneira
NGL Energy Partners  Expected to Post Earnings of $0.45 Per Share
NGL Energy Partners Expected to Post Earnings of $0.45 Per Share


© 2006-2018 Ticker Report. Google+.